Oculis Holding AG will present the Phase 2 ACUITY trial results for its neuro‑protective candidate Privosegtor at the North American Neuro‑Ophthalmology Society (NANOS) 52nd Annual Meeting in Boston, MA, from March 20‑24, 2026, with the presentation scheduled for Monday, March 23, 2026 at 8:48 AM EDT. The presentation will focus on improved low‑contrast visual acuity and reduced retinal ganglion cell loss in patients with acute optic neuritis, underscoring Privosegtor’s potential as the first neuro‑protective therapy for optic neuropathies.
The Phase 2 ACUITY trial demonstrated a statistically significant improvement in low‑contrast visual acuity and a meaningful reduction in retinal ganglion cell loss compared with placebo. These findings support the drug’s mechanism of action, which allows it to cross both the blood‑brain and retinal barriers. The results also reinforce the Breakthrough Therapy designation granted by the U.S. Food and Drug Administration, a designation that can accelerate regulatory review and streamline the path to market.
Oculis is advancing the PIONEER registrational program, which includes the PIONEER‑1 trial that began in Q4 2025. The program targets optic neuritis and non‑arteritic anterior ischemic optic neuropathy (NAION), a combined U.S. market estimated to exceed $7 billion. CEO Riad Sherif emphasized the significance of the trial results, stating, "Our commitment to advancing the field of neuro‑ophthalmology has never been stronger. The ACUITY Phase 2 results with Privosegtor highlight meaningful progress toward delivering a much‑needed neuroprotective therapy to patients with optic neuritis and other optic neuropathies." He added, "Today's Breakthrough Therapy Designation underscores Privosegtor's significant potential as a first‑of‑its‑kind neuroprotective therapy for people living with optic neuritis, and highlights our commitment to redefining what's possible for patients suffering from neuroaxonal loss."
In addition to Privosegtor, Oculis is progressing other pipeline candidates, including OCS‑01 for diabetic macular edema, with Phase 3 topline results expected in Q2 2026, and Licaminlimab for dry eye disease. The company’s focus on neuro‑ophthalmology and related indications positions it to address a substantial unmet medical need and to potentially expand Privosegtor’s applicability to other neuro‑ophthalmic and neurological diseases.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.